Farletuzumab-exatecan

Farletuzumab-exatecan (SYS6041) is an antibody-drug conjugate developed by CSPC Megalith Biopharmaceutical. Its target is Folate receptor alpha (the sponsor names Folate receptor alpha (FRα)). The sponsor states: SYS6041 (farletuzumab-exatecan) is an antibody-drug conjugate targeting human folate receptor alpha with a topoisomerase I inhibitor payload, given by intravenous injection on day 1 of each three-week cycle. ClinicalTrials.gov describes the intervention as: Farletuzumab-exatecan antibody-drug conjugate targeting human FRα. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT07744763, plans to enrol 260 participants with primary completion expected 2027-03-28. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.